Posts

Electra Targets Nearly $300M IPO

on

Enhertu gains a potential first-line foothold in HER2-mutant NSCLC, but oral TKIs remain credible competitors

on

Enhertu Approved in the EU as First Tumor Agnostic HER2-Directed Therapy for Previously Treated HER2-Positive Metastatic Solid Tumors

on

9 Companies Hiring in New Jersey - BioSpace

on

FDA Grants Daiichi Sankyo and AstraZeneca’s Datroway a Key Breast Cancer Approval

on

Daiichi Sankyo Targets Nearly $15B in Oncology Sales by 2030 via ADC Franchise Expansion

on

Daiichi Sankyo's ADC Manufacturing Investments and Market Position

on

FDA Action Alert: Upcoming Decisions on Argenx, AstraZeneca/Daiichi Sankyo, Biogen/Eisai, and Cingulate

on

Daiichi Sankyo Postpones FY2026 Earnings Announcement to May 11, Shares Plunge 10%

on

FDA Lifts Partial Hold on Merck and Daiichi Sankyo's B7-H3 ADC Trial for Lung Cancer[6]

on

FDA places partial clinical hold on Merck and Daiichi Sankyo’s I-DXd lung cancer trial after interstitial lung disease deaths

on

AstraZeneca and Daiichi Sankyo Report Landmark Results for Datroway in Triple-Negative Breast Cancer

on

Daiichi and Merck's Lung Cancer ADC Achieves 48% Response Rate in Pivotal Trial

on

Merck, Daiichi Sankyo Withdraw FDA Application for HER3-Targeting ADC After Survival Endpoint Miss

on

AstraZeneca, Daiichi say Enhertu delivers 'highly statistically significant' efficacy in first-line breast cancer

on

Daiichi turns to Nosis for AI-designed RNA delivery tech

on

FDA Approves Ono's Romvimza for Rare Joint Tumor, Challenging Daiichi Sankyo's Turalio

on

Enhertu Secures 7th FDA Approval for Expanded Use in HER2-Low and HER2-Ultralow Breast Cancer

on